Table 1.
Study characteristics
| Psychotherapy | Medication | Diagnosis | Mean age of sample | % female in sample | N se | Treatment duration (weeks) | N rand | Country | |
|---|---|---|---|---|---|---|---|---|---|
| Browne 2002[26] |
IPT |
Sertraline (SSRI) |
Dys, DD |
42.2 |
68 |
12 |
24 |
476 |
Canada |
| deMello 2001[27] |
IPT |
Moclobemide |
Dys, DD |
38.8 |
80 |
16 |
32 |
35 |
Brazil |
| Keller 2000[28] |
CBASP |
Nefazodone |
cMD, rec, DD |
43.0 |
65 |
16 |
12 |
453 |
USA |
| Kocsis 2009[13] |
CBASP/BSP |
SSRIs |
cMD, rec, DD |
45.4 |
55 |
16/18 |
12 |
491 |
USA |
| Markowitz 2005[29] |
IPT |
Sertraline (SSRI) |
Dys |
42.3 |
63 |
16 |
16 |
45 |
USA |
| Miller 1999[30] |
CBT |
Amitriptyline/Desipramine |
Dys |
37.4 |
81 |
40 |
20 |
26 |
USA |
| Ravindran 1999[31] |
CBT |
Sertraline (SSRI) |
Dys |
38.0 |
58 |
12 |
12 |
47 |
Canada |
| Schramm 2008[32] | IPT | Sertraline (SSRI)/Amitriptyline | cMD, DD | 42.8 | 67 | 15 | 5 | 45 | Germany |
N se = number of psychotherapy sessions; N rand = patients randomized to relevant study arms; IPT = Interpersonal Psychotherapy; CBASP = Cognitive Behavioural Analysis System of Psychotherapy; BSP = Brief Supportive Psychotherapy; CBT = Cognitive Behavioural Therapy; Dys = dysthymia; DD = double depression; cMD = chronic major depression; rec = recurrent depression without complete remission between episodes.